Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEFAL: Avastin vs Lucentis in Neovascular AMD
NCT01170767Phase 3Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Jun 2009
- Primary completion
- Dec 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Hospices Civils de Lyon. Started Jun 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01170767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01170767.